LENZ
Lenz Therapeutics
$5.70
+$0.22 (+4.01%)Jul 27, 2026
Key metrics
The numbers that frame LENZ today
- Market cap
- $178.72M
- P/E (TTM)
- -1.6
- EV / FCF
- -1.8
- Gross margin
- 92.9%
- EV / Sales
- 7.3
- ROIC
- -52.8%
- Div yield
- 0%
- Debt / equity
- 0.0
- 52wk Low
- $4.68
- 52wk High
- $50.19
Growth
Revenue and earnings trend for LENZ
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about LENZ
Is Lenz Therapeutics a good buy?
No. Lenz Therapeutics has poor quality and poor momentum. Both signals point to a weaker setup. Growth looks poor. That could put pressure on the long-term business case. We think Lenz Therapeutics is selling at a very high price.
What is the market capitalization of LENZ?
Lenz Therapeutics's market capitalization is $178.72M.
What is the P/E ratio for LENZ stock?
Lenz Therapeutics's current P/E ratio is -1.6.
What is the 52-week high for LENZ stock?
The 52-week high for Lenz Therapeutics is $50.19. The current close of $5.70 is 88.6% below that high.
What is the 52-week low for LENZ stock?
The 52-week low for Lenz Therapeutics is $4.68. The current close of $5.70 is 21.8% above that low.
Does LENZ stock pay dividends?
Lenz Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for LENZ?
Lenz Therapeutics's Debt / Equity ratio is 0.